Chloroquine Oral, Intramuscular and Darifenacin Hydrobromide
Determining the interaction of Chloroquine Oral, Intramuscular and Darifenacin Hydrobromide and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Chloroquine may increase the blood levels of darifenacin. In some cases, this can increase side effects such as nausea, dry mouth, abdominal pain, constipation, and heartburn. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. According to the product labeling, coadministration of darifenacin (30 mg once daily) with the mixed CYP450 inhibitor cimetidine resulted in a 42% increase in the mean darifenacin steady-state peak plasma concentration (Cmax) and a 34% increase in the systemic exposure (AUC) compared to administration of darifenacin alone. The potent CYP450 2D6 inhibitor paroxetine (20 mg) increased steady-state AUC of darifenacin (30 mg once daily) by 33%. Erythromycin, a CYP450 3A4 inhibitor, increased the mean steady-state Cmax and AUC of darifenacin (30 mg once daily) by 128% and 95%, respectively. Fluconazole, another 3A4 inhibitor, increased these values by 88% and 84%, respectively.
MANAGEMENT: Pharmacologic response to darifenacin should be monitored more closely whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the darifenacin dosage adjusted if necessary. Patients should be advised to contact their physician if they experience undue adverse effects of darifenacin such as severe abdominal pain or constipation for 3 or more days.
- "Product Information. Enablex (darifenacin)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: chloroquine
Brand name: Aralen Phosphate, Aralen Hydrochloride
Synonyms: Chloroquine
Generic Name: darifenacin
Brand name: Enablex
Synonyms: Darifenacin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Chloroquine Oral, Intramuscular-Darolutamide
- Chloroquine Oral, Intramuscular-Darpaz
- Chloroquine Oral, Intramuscular-Darunavir
- Chloroquine Oral, Intramuscular-Darunavir and Cobicistat
- Chloroquine Oral, Intramuscular-Darunavir Oral Suspension
- Chloroquine Oral, Intramuscular-Darunavir Tablets
- Darifenacin Hydrobromide-Chloroquine Phosphate
- Darifenacin Hydrobromide-Chlorothiazide
- Darifenacin Hydrobromide-Chlorothiazide Injection
- Darifenacin Hydrobromide-Chlorothiazide Intravenous
- Darifenacin Hydrobromide-Chlorothiazide oral/injection
- Darifenacin Hydrobromide-Chlorothiazide Sodium